Acknowledgement
본 연구는 2021년 식품의약품안전처의 연구과제(21153 MFDS602)로 수행하였습니다.
References
- Statistics Korea. Senior Citizen Statistics Data in 2022. Korea National Statistics Office. 2022. Available from https://kostat.go.kr/board.es?mid=a10301010000&bid=10820&tag=&act=view&list_no=420896&ref_bid, Accessed June 12, 2023
- Yun SH, Kim DS, Chae JM, Choi YM, Cho HJ, Establishment of criteria for managing inappropriate polypharmacy in the elderly. In: Health Insurance Review & Assessment service. 2023. Available from https://repository.hira.or.kr/handle/2019.oak/3086, Accessed June 21, 2023
- Park HY, Sohn HS, Kwon JW. Reviews on the current status and appropriate management of polypharmacy in south korea. Korean J Clin Pharm 2018;28(1):1-9. https://doi.org/10.24304/kjcp.2018.28.1.1
- Seo DS, Yoon JL, Kim SJ, Park JS, Lee WJ, Kim MY. Polypharmacy in older patients admitted to a general hospital. Ann Geriatr Med Res, 2012;16(3):133-40.
- Lee JK. Factors associated with drug misuse behaviors among polypharmacy elderly. Korean Journal of Adult Nursing 2011;23(6):554-63.
- Cheong SJ, Yoon JL, Choi SH, Kim MY, Cho JJ, Ju YS. The effect of polypharmacy on mortality in the elderly. KJFP 2016;6(6):643-50. https://doi.org/10.21215/kjfp.2016.6.6.643
- Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: A scientific statement from the american heart association. Circulation 2020;142(15):e214-33. https://doi.org/10.1161/CIR.0000000000000905
- Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med. 1989;111:549-51. https://doi.org/10.7326/0003-4819-111-7-549
- Hussaarts KG, Berger FA, Binkhorst L, et al. The risk of qtc-interval prolongation in breast cancer patients treated with tamoxifen in combination with serotonin reuptake inhibitors. Pharm Res 2020;37:1-8. https://doi.org/10.1007/s11095-019-2746-9
- Khan Q, Ismail M, Haider I, Khan F. Prevalence of qt interval prolonging drug-drug interactions (qt-ddis) in psychiatry wards of tertiary care hospitals in pakistan: A multicenter cross-sectional study. Int J Clin Pharm 2017;39:1256-64. https://doi.org/10.1007/s11096-017-0532-5
- Chastang A, Renet S, Corny J, et al. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other qt-prolonging drugs. Int J Clin Pharm 2019;41:42-8. https://doi.org/10.1007/s11096-018-0724-7
- Momo K, Kobayashi H, Sugiura Y, Yasu T, Koinuma M, Kuroda Si. Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data. PLoS One 2019;14(12):e0225297. https://doi.org/10.1371/journal.pone.0225297
- Wei A, Peng J, Gu Z, Li J. Qtc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature. Medicine 2017;96(49):e9071. https://doi.org/10.1097/MD.0000000000009071
- Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and qt prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials. BMC Pharmacol Toxicol 2016;17:1-15. https://doi.org/10.1186/s40360-016-0053-1
- Berger FA, van der Sijs H, van Gelder T, Kuijper AF, van den Bemt PM, Becker ML. Comparison of two algorithms to support medication surveillance for drug-drug interactions between qtc-prolonging drugs. Int J Med Inform 2021;145:104329. https://doi.org/10.1016/j.ijmedinf.2020.104329
- Romero L, Cano J, Gomis-Tena J, et al. In silico qt and apd prolongation assay for early screening of drug-induced proarrhythmic risk. J Chem Inf Model 2018;58(4):867-78. https://doi.org/10.1021/acs.jcim.7b00440
- Wisniowska B, Polak S. The role of interaction model in simulation of drug interactions and qt prolongation. Curr Pharmacol Rep 2016;2:339-44. https://doi.org/10.1007/s40495-016-0075-9
- Lee W, Windley MJ, Vandenberg JI, Hill AP. In vitro and in silico risk assessment in acquired long qt syndrome: The devil is in the details. Front Physiol 2017;8:934. https://doi.org/10.3389/fphys.2017.00934
- JE NK, Kim DS, KIM GJ, Lee S. Pharmacodynamic drug-drug interactions considered to be added in the list of contraindications with pharmacological classification in korea. Korean J Clin Pharm 2015;25(2):120-8.
- Flockhart DA, Thacker D, McDonald C, Desta Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Available from https://drug-interactions.medicine.iu.edu. Accessed November 1, 2021.
- Cohen N, Modai D, Golik A, Eshkoly M, Theitler J, Scapa E. Cimetidine-related cardiac conduction disturbances and confusion. J Clin Gastroenterol 1989;11(1):68-9. https://doi.org/10.1097/00004836-198902000-00017
- Correa A, Rochlani Y, Aronow WS. Current pharmacotherapeutic strategies for cardiac arrhythmias in heart failure. Expert Opin Pharmacother 2020;21(3):339-52. https://doi.org/10.1080/14656566.2019.1703950
- Fox H, Bitter T, Horstkotte D, Oldenburg O. Sleep-disordered breathing and arrhythmia in heart failure patients. Sleep Med Clin 2017;12(2):229-41. https://doi.org/10.1016/j.jsmc.2017.01.003
- Singh BN. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Fail Rev 2002;7:285-300. https://doi.org/10.1023/A:1020001912248
- Romano IJ, Lippolis A, D'Anna M, Gentile F. Cardiac arrhythmias and acute cerebrovascular events: A case of qt prolongation and torsades de pointes early after right insular stroke. J Stroke Cerebrovasc Dis 2019;28(11):104308. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104308
- Ruthirago D, Julayanont P, Tantrachoti P, Kim J, Nugent K. Cardiac arrhythmias and abnormal electrocardiograms after acute stroke. Am J Med Sci 2016;351(1):112-8. https://doi.org/10.1016/j.amjms.2015.10.020
- Koppikar S, Baranchuk A, Guzman JC, Morillo CA. Stroke and ventricular arrhythmias. Int J Cardiol 2013;168(2):653-9. https://doi.org/10.1016/j.ijcard.2013.03.058
- Adejumo AC, Adejumo KL, Akanbi O, et al. Predictors, burden and impact of cardiac arrhythmias among patients hospitalized with end-stage liver disease. Heart Lung 2020;49(1):73-9. https://doi.org/10.1016/j.hrtlng.2019.07.002
- Trevisani F, Merli M, Savelli F, et al. Qt interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38(4):461-7. https://doi.org/10.1016/S0168-8278(03)00057-6
- Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Prolonged q-tc interval in mild portal hypertensive cirrhosis. J Hepatol 2005;43(4):637-44. https://doi.org/10.1016/j.jhep.2005.04.015
- Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in copd: Part 1: Saskatchewan cohort study. Chest 2012;142(2):298-304. https://doi.org/10.1378/chest.10-2499
- Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in copd: Part 2: Reassessment in the larger quebec cohort. Chest 2012;142(2):305-11. https://doi.org/10.1378/chest.11-1597
- Rusinowicz T, Zielonka TM, Zycinska K. Cardiac arrhythmias in patients with exacerbation of copd. Clinical Management of Pulmonary Disorders and Diseases 2017;1022:53-62. https://doi.org/10.1007/5584_2017_41
- Han S-J. Amiodarone. International Journal of Arrhythmia 2013;14(2):4-9.
- Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990;65(19):42-8. https://doi.org/10.1016/0002-9149(90)90125-K
- Aufderheide TP. Arrhythmias associated with acute myocardial infarction and thrombolysis. Emerg Med Clin North Am 1998;16(3):583-600. https://doi.org/10.1016/S0733-8627(05)70019-5